PRF Technologies (PRFX) Preferred Stock Liabilities (2019 - 2020)
PRF Technologies (PRFX) posted quarterly Preferred Stock Liabilities of $6.6 million for Q2 2020, little changed on a QoQ basis from $6.6 million in Q4 2019.
PRF Technologies (PRFX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
PRF Technologies (PRFX) has reported Preferred Stock Liabilities for 2 consecutive years, with $6.6 million the latest figure, recorded in Q2 2020.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $6.6 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $6.6 million (changed N/A YoY) and the FY2019 annual result came in at $6.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $6.6 million in Q2 2020 per PRFX's latest filing, from $6.6 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for PRFX reached as high as $6.6 million in Q4 2019 and fell as low as $6.6 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 6.62 Mn |
| Dec 31, 2019 | 6.62 Mn |